MX2017003789A - Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar. - Google Patents

Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.

Info

Publication number
MX2017003789A
MX2017003789A MX2017003789A MX2017003789A MX2017003789A MX 2017003789 A MX2017003789 A MX 2017003789A MX 2017003789 A MX2017003789 A MX 2017003789A MX 2017003789 A MX2017003789 A MX 2017003789A MX 2017003789 A MX2017003789 A MX 2017003789A
Authority
MX
Mexico
Prior art keywords
intermediates
preparation
processes
c5ar antagonists
c5ar
Prior art date
Application number
MX2017003789A
Other languages
English (en)
Other versions
MX368492B (es
Inventor
Zhang Penglie
Tanaka Hiroko
Punna Sreenivas
Powers Jay
Lui Rebecca
Krasinski Antoni
Fan Pingchen
Kalisiak Jaroslaw
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2017003789A publication Critical patent/MX2017003789A/es
Publication of MX368492B publication Critical patent/MX368492B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan intermediarios y métodos para la preparación de compuestos antagonistas de C5aR seleccionados.
MX2017003789A 2014-09-29 2015-09-28 Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar. MX368492B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462057107P 2014-09-29 2014-09-29
PCT/US2015/052697 WO2016053890A1 (en) 2014-09-29 2015-09-28 PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS

Publications (2)

Publication Number Publication Date
MX2017003789A true MX2017003789A (es) 2017-08-02
MX368492B MX368492B (es) 2019-10-04

Family

ID=55583729

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003789A MX368492B (es) 2014-09-29 2015-09-28 Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.
MX2019011911A MX2019011911A (es) 2014-09-29 2017-03-23 Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019011911A MX2019011911A (es) 2014-09-29 2017-03-23 Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.

Country Status (19)

Country Link
US (5) US9745268B2 (es)
EP (2) EP3682879B1 (es)
JP (1) JP6898229B6 (es)
KR (2) KR102593431B1 (es)
CN (2) CN113121415A (es)
AU (2) AU2015324111B2 (es)
BR (1) BR112017006232B1 (es)
CA (2) CA2960733C (es)
DK (1) DK3200791T3 (es)
ES (2) ES2926828T3 (es)
IL (1) IL251061B (es)
MA (1) MA52308A (es)
MX (2) MX368492B (es)
NZ (2) NZ767823A (es)
PL (1) PL3200791T3 (es)
PT (1) PT3200791T (es)
RU (1) RU2712233C2 (es)
SG (1) SG11201702185UA (es)
WO (1) WO2016053890A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009330194B2 (en) 2008-12-22 2015-07-09 Chemocentryx, Inc. C5aR antagonists
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
BR112017006232B1 (pt) 2014-09-29 2022-10-11 Chemocentryx, Inc. Processos e intermediários na preparação de antagonistas de c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
CA3077395A1 (en) * 2017-10-30 2019-05-09 Chemocentryx, Inc. Deuterated compounds as immunomodulators
WO2019236820A1 (en) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosing and effect of c5a antagonist with anca-associated vasculitis
ES2943492T3 (es) 2018-11-30 2023-06-13 Chemocentryx Inc Formulación de cápsulas
KR102207333B1 (ko) * 2019-09-09 2021-01-27 성균관대학교산학협력단 4중 연속 고리 화합물의 신규한 제조방법
AU2020378397A1 (en) 2019-11-08 2022-06-23 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor
WO2021092295A1 (en) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Salt forms of a complement component c5a receptor
AU2020378061A1 (en) * 2019-11-08 2022-05-26 Chemocentryx, Inc. Free base crystalline form of a complement component C5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
CN113957106B (zh) * 2021-11-03 2024-04-19 暨明医药科技（苏州）有限公司 一种Avacopan及其中间体的制备方法
CN114262291B (zh) * 2022-01-04 2023-05-19 重庆医科大学 一种阿伐可泮的合成方法
WO2023158722A2 (en) 2022-02-16 2023-08-24 Teva Pharmaceuticals International Gmbh Processes for preparation of avacopan and intermediates thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US6410540B1 (en) 1998-08-28 2002-06-25 Scios, Inc. Inhibitors of p38-αkinase
RU2197288C2 (ru) 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
WO2002049993A2 (en) 2000-09-29 2002-06-27 Neurogen Corporation High affinity small molecule c5a receptor modulators
JP2003532726A (ja) 2000-05-05 2003-11-05 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
AU2001268724B2 (en) * 2000-06-29 2005-06-16 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
CA2418652C (en) 2000-08-10 2010-03-23 Mitsubishi Pharma Corporation Novel 3-substituted urea derivatives and medicinal use thereof
CN102050758A (zh) 2000-09-14 2011-05-11 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
DE10231783A1 (de) 2001-07-19 2003-03-20 Luk Lamellen & Kupplungsbau System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges
EP1425042B2 (en) 2001-08-17 2016-02-10 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
JP4347050B2 (ja) 2001-09-21 2009-10-21 田辺三菱製薬株式会社 ３−置換−４−ピリミドン誘導体
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
CA2480082A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
AU2003257094A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
AU2003290605A1 (en) 2002-11-05 2004-06-03 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004043925A2 (en) 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EP1853586B1 (en) 2005-02-18 2013-07-24 AstraZeneca AB Antibacterial piperidine derivatives
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007051062A2 (en) 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
EP1951663B1 (en) 2005-11-24 2016-07-20 Dompé farmaceutici s.p.a. (r)-arylkylamino derivatives and pharmaceutical compositions containing them
BR122017024057B8 (pt) 2006-03-15 2021-05-25 Alexion Pharma Inc anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
US8198266B2 (en) 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
KR20100027241A (ko) 2007-06-29 2010-03-10 토렌트 파마슈티칼스 리미티드 Ｈｓｐ 인듀서로서 신규의 치환된 피페리돈
CA2737219C (en) 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
EP2331561A4 (en) 2008-09-03 2013-02-27 Xenome Ltd PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
DK2894165T3 (da) 2008-11-10 2023-03-20 Alexion Pharma Inc Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
AU2009330194B2 (en) * 2008-12-22 2015-07-09 Chemocentryx, Inc. C5aR antagonists
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
RS56332B1 (sr) * 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
CN104662015B (zh) 2012-06-20 2017-03-29 诺华股份有限公司 补体途径调节剂及其用途
JP2016523829A (ja) 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
BR112017006232B1 (pt) * 2014-09-29 2022-10-11 Chemocentryx, Inc. Processos e intermediários na preparação de antagonistas de c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
CN116635075A (zh) 2020-12-21 2023-08-22 坎莫森特里克斯公司 使用c5a抑制剂治疗c3肾小球病

Also Published As

Publication number Publication date
US20230008966A1 (en) 2023-01-12
KR102593431B1 (ko) 2023-10-23
KR20170085492A (ko) 2017-07-24
ES2926828T3 (es) 2022-10-28
EP3682879A1 (en) 2020-07-22
RU2017114960A3 (es) 2019-04-10
US20200354320A1 (en) 2020-11-12
SG11201702185UA (en) 2017-04-27
US20160090357A1 (en) 2016-03-31
AU2015324111A1 (en) 2017-04-06
WO2016053890A1 (en) 2016-04-07
RU2017114960A (ru) 2018-11-07
JP6898229B6 (ja) 2021-07-28
CA3220371A1 (en) 2016-04-07
AU2021204209A1 (en) 2021-07-15
CA2960733A1 (en) 2016-04-07
AU2015324111B2 (en) 2021-04-01
EP3200791B1 (en) 2020-04-22
DK3200791T3 (da) 2020-05-25
US11845729B2 (en) 2023-12-19
IL251061A0 (en) 2017-04-30
KR20230149873A (ko) 2023-10-27
JP2017529378A (ja) 2017-10-05
US10266492B2 (en) 2019-04-23
MX2019011911A (es) 2019-11-25
CN106999481B (zh) 2021-04-16
EP3682879B1 (en) 2022-08-03
US20180072668A1 (en) 2018-03-15
US20190276402A1 (en) 2019-09-12
NZ730123A (en) 2023-05-26
CA2960733C (en) 2024-01-09
MA52308A (fr) 2021-02-24
EP3200791A4 (en) 2018-06-13
BR112017006232A2 (pt) 2017-12-12
MX368492B (es) 2019-10-04
ES2802428T3 (es) 2021-01-19
BR112017006232B1 (pt) 2022-10-11
EP3200791A1 (en) 2017-08-09
IL251061B (en) 2019-09-26
CN113121415A (zh) 2021-07-16
US9745268B2 (en) 2017-08-29
US10532982B2 (en) 2020-01-14
JP6898229B2 (ja) 2021-07-07
PT3200791T (pt) 2020-05-06
AU2021204209B2 (en) 2022-10-06
PL3200791T3 (pl) 2020-08-10
CN106999481A (zh) 2017-08-01
NZ767823A (en) 2023-05-26
RU2712233C2 (ru) 2020-01-27

Similar Documents

Publication Publication Date Title
MX2019011911A (es) Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.
ZA201806632B (en) Soluble c5ar antagonists
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
IL250582B (en) Compositions and methods for early screening of medical components
HK1250146A1 (zh) 抗前-bcr拮抗劑和方法
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
HK1246288A1 (zh) S1pr2拮抗劑及其用途
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
IL251588A0 (en) Methods and preparations for increasing the potency of antifungal agents
EP3140275A4 (en) Bh4 antagonists and methods related thereto
ZA201807767B (en) Angiotensin-1-receptor antagonists
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
NZ744340A (en) Anti-jagged1 antibodies and methods of use

Legal Events

Date Code Title Description
FG Grant or registration